Avalia??o do efeito da liraglutida, um an?logo do GLP-1, na prolifera??o das c?lulas pr?-osteobl?sticas MC3T3 E1

• Main Author: Marques, Juliana Romeu
• Other Authors: Oliveira, Jarbas Rodrigues de
• Format: Others
• Language: Portuguese
• Published: Pontif?cia Universidade Cat?lica do Rio Grande do Sul 2016
• Subjects: PR?-OSTEOBLASTOS; APOPTOSE; MEDICAMENTOS - EFEITOS ADVERSOS; BIOLOGIA CELULAR; CIENCIAS BIOLOGICAS::BIOLOGIA GERAL
• Online Access: http://tede2.pucrs.br/tede2/handle/tede/6674

Submitted by Setor de Tratamento da Informa??o - BC/PUCRS ([e-mail]) on 2016-05-17T12:16:55Z No. of bitstreams: 1 DIS_JULIANA_ROMEU_MARQUES_COMPLETO.pdf: 1432001 bytes, checksum: 2d6dc8303449f3f554bf97804d426795 (MD5) === Made available in DSpace on 2016-05-17T12:16:55Z (GMT). No. of bitstreams: 1 DIS_JULIANA_ROMEU_MARQUES_COMPLETO.pdf: 1432001 bytes, checksum: 2d6dc8303449f3f554bf97804d426795 (MD5) Previous issue date: 2016-02-16 === Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior - CAPES === The liraglutide is a glucagon-like peptide 1 (GLP-1) based therapy and an alternative treatment to type 2 diabetes mellitus (T2DM). Apart from its hypogliycemic effect, the drug has been also associated with the prevention of cardiovascular diseases, regulation of blood lipid and anti-inflammatory action. Reports indicate, however, that liraglutide can increase the risk of thyroid cancer and cause pancreatitis. Besides, studies demonstrated that some analogues of GLP-1 have a deleterious bone effect, while others demonstrated to be benefic to the bone. The aim of this study was to evaluate the effect in vitro of liraglutide in mouse pre-osteoblastic cells, MC3T3-E1. The results demonstrated that liraglutide significantly decreased the number of viable cells without inducing apoptosis. The mechanism of this effect is associated to the reactive oxygen species production (ROS), which resulted in an increase of cell autophagy. The decreased number of viable cells indicates therefore that liraglutide may affect the bone formation. === A liraglutida ? uma terapia baseada no horm?nio GLP-1 utilizada como tratamento alternativo para a diabetes mellitus tipo 2 (DM2). O medicamento, al?m do efeito hipoglicemiante, tem sido associado ? preven??o de doen?as cardiovasculares, diminui??o dos lip?deos no sangue e ? a??o anti-inflamat?ria. Relatos indicam, por?m, que a liraglutida pode aumentar o risco de c?ncer de tireoide e provocar pancreatite. Al?m disso, estudos demonstram que alguns an?logos do GLP-1 t?m efeito ?sseo delet?rio, enquanto outros t?m efeito ben?fico. O objetivo deste estudo ? avaliar o efeito da liraglutida sobre o crescimento de c?lulas pr?-osteobl?sticas (MC3T3-E1). Os resultados t?m demonstrado que a liraglutida diminuiu significativamente o n?mero de c?lulas sem induzir a apoptose. O mecanismo deste efeito est? associado ? produ??o de esp?cies reativas de oxig?nio, que resulta em um aumento da autofagia das c?lulas, indicando, desta forma, que pode afetar a forma??o ?ssea.